G. Raskob

Internal Medicine · 2003–2017

A researcher in the Science corpus: 18 papers; trusts 6 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Internal Medicine — 106 citations into it
• Cardiology and Cardiovascular Medicine — 101 citations into it
• Surgery — 55 citations into it
• Hematology — 47 citations into it

Whom G. Raskob trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Heit
2. Jason G. Andrade
3. S. Schulman
4. R. White

Who trusts G. Raskob overall

1. Aaron M. Wendelboe

Papers from G. Raskob's perspective

Ordered by how strongly the researchers G. Raskob trusts endorse each paper. Same corpus, a different order for every researcher.

1. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. (Circulation Research)
2. The epidemiology of venous thromboembolism in the community. (Arteriosclerosis, Thrombosis and Vascular Biology)
3. AGE STANDARDIZATION OF RATES: A NEW WHO STANDARD
4. Venous thromboembolism: a public health concern. (American Journal of Preventive Medicine)
5. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (New England Journal of Medicine)
6. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (Chest)
7. Generalized Linear Models
8. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. (Archives of Internal Medicine)
9. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (Journal of Clinical Epidemiology)
10. GRADE guidelines: 2. Framing the question and deciding on important outcomes. (Journal of Clinical Epidemiology)

Their papers

• Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. (2006) — 1,269 citations
• Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism (2017) — 874 citations
• Global Burden of Thrombosis: Epidemiologic Aspects. (2016) — 1,153 citations
• Thrombosis: A major contributor to global disease burden (2014) — 923 citations
• Thrombosis: A Major Contributor to Global Disease Burden (2014) — 635 citations
• Apixaban for extended treatment of venous thromboembolism. (2013) — 1,268 citations
• Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. (2013) — 1,829 citations
• Oral apixaban for the treatment of acute venous thromboembolism. (2013) — 2,195 citations
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (2012) — 1,719 citations
• Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. (2010) — 781 citations
• Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. (2010) — 796 citations
• Oral rivaroxaban for symptomatic venous thromboembolism. (2010) — 2,252 citations
• Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. (2010) — 1,180 citations
• Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. (2009) — 671 citations
• Apixaban or enoxaparin for thromboprophylaxis after knee replacement. (2009) — 726 citations
• Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) — 2,089 citations
• Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) — 1,347 citations
• ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. (2003) — 711 citations